0000950170-24-069929.txt : 20240606 0000950170-24-069929.hdr.sgml : 20240606 20240606163354 ACCESSION NUMBER: 0000950170-24-069929 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240605 FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Powell Lynne CENTRAL INDEX KEY: 0001631667 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 241025954 MAIL ADDRESS: STREET 1: 4505 EMPEROR BLVD. STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: PROGENITY, INC. DATE OF NAME CHANGE: 20150617 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 4 1 ownership.xml 4 X0508 4 2024-06-05 0001580063 BIORA THERAPEUTICS, INC. BIOR 0001631667 Powell Lynne C/O BIORA THERAPEUTICS, INC. 4330 LA JOLLA VILLAGE DRIVE, SUITE 300 SAN DIEGO CA 92122 true false false false false Common Stock 2024-06-05 4 A false 12500 0 A 30746 D Stock Option (Right to Buy) 0.70 2024-06-05 4 A false 12500 0 A 2034-06-05 Common Stock 12500 12500 D Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. /s/ Clarke Neumann, Attorney-in-Fact for Lynne Powell 2024-06-06